NephroGenex Reports Positive Results for QT Study of Pyridorin

NephroGenex, Inc. (Nasdaq: NRX), a pharmaceutical company focused on thedevelopment of therapeutics to treat kidney disease, today announced theCompany has successfully completed a thorough QT/QTc (TQT) cardiac safetystudy on Pyridorin. This study assesses a drug's risk of QT prolongation andits proarrhythmic potential, and is a standard component of all clinicaldevelopment programs for new molecular entities.Pyridorin showed no effect on the QT/QTc interval at the expected therapeuticdose of 300 mg and at a higher dose of 1200 mg. In previous Phase 1 and Phase2 studies, Pyridorin has shown no effect on the QT/QTc interval in patientswith diabetic nephropathy.“These are important study results that support the use of Pyridorin inpatients with diabetic nephropathy, many of whom suffer from cardiovasculardisease. They are also important given the concerns over cardiac safety seenwith other therapies in development for this disease,” said Chief ExecutiveOfficer Pierre Legault. “The overall excellent safety profile we arecontinuing to see, along with the promising efficacy shown in our Phase 2trials, continues to suggest that Pyridorin has the potential to broadlyaddress the unmet therapeutic needs of the more than 6 million diabeticpatients with kidney disease.”